Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2025-01-01 DOI:10.1002/wnan.70004

Laxman Devkota, Rohan Bhavane, Cristian T Badea, Eric A Tanifum, Ananth V Annapragada, Ketan B Ghaghada

{"title":"Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities.","authors":"Laxman Devkota, Rohan Bhavane, Cristian T Badea, Eric A Tanifum, Ananth V Annapragada, Ketan B Ghaghada","doi":"10.1002/wnan.70004","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical availability of photon-counting computed tomography (PCCT) has ushered in a new era of CT imaging. Spectral imaging coupled with superior contrast resolution, and ultrahigh spatial resolution (200 μm) offered by PCCT has the potential to revolutionize value-driven imaging. The potential of multicolor PCCT has generated excitement, and renewed interest, in novel contrast agent development for comprehensive disease interrogation, prediction and monitoring of treatment outcomes. Nanoparticles provide a versatile and powerful platform for the development of next generation contrast agents for spectral PCCT. In this article, we review recent developments and use of nanoparticle contrast agents for PCCT. We also discuss future research and translational opportunities for nanoparticle-based CT contrast agents enabled by the advent of PCCT and describe key considerations for their clinical translation.</p>","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"17 1","pages":"e70004"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874078/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/wnan.70004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The clinical availability of photon-counting computed tomography (PCCT) has ushered in a new era of CT imaging. Spectral imaging coupled with superior contrast resolution, and ultrahigh spatial resolution (200 μm) offered by PCCT has the potential to revolutionize value-driven imaging. The potential of multicolor PCCT has generated excitement, and renewed interest, in novel contrast agent development for comprehensive disease interrogation, prediction and monitoring of treatment outcomes. Nanoparticles provide a versatile and powerful platform for the development of next generation contrast agents for spectral PCCT. In this article, we review recent developments and use of nanoparticle contrast agents for PCCT. We also discuss future research and translational opportunities for nanoparticle-based CT contrast agents enabled by the advent of PCCT and describe key considerations for their clinical translation.

查看原文本刊更多论文

光子计数计算机断层扫描的纳米颗粒造影剂：最近的发展和未来的机会。

光子计数计算机断层扫描（PCCT）的临床应用开创了CT成像的新时代。PCCT提供的光谱成像加上卓越的对比度分辨率和超高空间分辨率（200 μm），有可能彻底改变价值驱动的成像。多色PCCT的潜力引起了人们的兴奋，并重新引起了人们对新型造影剂开发的兴趣，这种造影剂可用于全面的疾病询问、预测和监测治疗结果。纳米粒子为下一代光谱PCCT造影剂的开发提供了一个多功能和强大的平台。在本文中，我们回顾了纳米颗粒造影剂在PCCT中的最新发展和应用。我们还讨论了PCCT出现后纳米颗粒CT造影剂的未来研究和转化机会，并描述了其临床转化的关键考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

CiteScore

17.60

自引率

0.00%

发文量